Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC

Inclusion Criteria: * Signed written informed consent obtained prior to any trial-related procedures. * Male or female， ≥18 years and ≤75 years. * Histologically confirmed unresectable advanced or metastatic intrahepatic cholangiocarcinoma (ICC). Patients who developed recurrence more than 6 months after radical surgery are eligible. If adjuvant therapy (chemotherapy and/or radiotherapy) was received, recurrence must have occurred more than 6 months after completion of adjuvant therapy. * At least one measurable tumor lesion according to RECIST version 1.1 criteria. * No prior systemic therapy (chemotherapy, targeted therapy, or immunotherapy) for advanced/metastatic disease. * Life expectancy of at least 12 weeks. * ECOG Performance Status (PS) of 0 or 1. * Subjects must meet the following laboratory parameters: 1)Absolute Neutrophil Count (ANC): ≥ 1.5 × 10⁹/L (without granulocyte colony-stimulating factor support within the last 14 days). 2)Platelets: ≥ 100 × 10⁹/L (without transfusion within the last 14 days). 3)Hemoglobin: \> 9 g/dL (without transfusion or erythropoietin use within the last 14 days). 4)Total Bilirubin: ≤ 1.5 × Upper Limit of Normal (ULN). 5)Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT): ≤ 2.5 × ULN. 6)Creatinine Clearance: Calculated creatinine clearance (using the Cockcroft-Gault formula) ≥ 60 mL/min. * The subject is willing and able to comply with the protocol during the study period, including receiving treatment, adhering to contr…